Tandem Diabetes Care, Inc.

Good day, and thank you for standing by. Welcome to Tandem Diabetes Care First Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Susan Morrison, Executive Vice President, Chief Administrator Officer. Please go ahead.

Hello, everyone, and welcome to Tandem's first quarter earnings call for 2023. We'd like to remind everyone that today's discussion will include forward-looking statements. These statements reflect management's expectations about future events, product development timelines, and financial performance and operating plans. and speak only as of today's date. There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements. A list of factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is highlighted in our press release issued earlier today and under the risk factors portion and elsewhere in our most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in our other SEC filings. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or other factors. Today's discussion will also include references to a number of GAAP and non-GAAP financial measures. Non-GAAP financial measures are provided to give our investors information that we believe is indicative of our core operating performance. and reflects our ongoing business operations. We believe these non-GAAP financial measures facilitate better comparisons of operating results across reporting periods. Any non-GAAP information presented should not be considered as a substitution, independently or superior to results prepared in accordance with GAAP. Please refer to our earnings release, quarterly report on Form 10-Q, and the Investor Center portion of our website for a reconciliation of these measures to their most directly comparable GAAP financial measure. Today's call participants include John Sheridan, our President and CEO, Brian Hanson, our Executive Vice President and Chief Commercial Officer, and Lee Vossler, our Executive Vice President and Chief Financial Officer. Following their prepared remarks, we'll open up the call for questions. Thank you in advance for limiting yourself to one question before getting back into the queue. John, you're welcome to begin.

Thanks, Susan. And thank you everyone for joining us on today's call. We're coming out of the first quarter with confidence about our ability to achieve our key operational and commercial goals we set for this year. We continue to expand the insulin pump market while capturing competitive share and growing the number of tandem customers purchasing a T-Slim once again. This is a meaningful achievement in a highly competitive environment and a testament to our talented employees and our number one rated T-Slim X2 with Control IQ technology. Internally, our teams continue to prepare for the launch of multiple new products in 2023. I'll talk more about each of these later in my comments. But overall, there's an enthusiasm at tandem as we approach being able to offer another wave of innovative products to the diabetes community. With these launches, we'll be building upon our reputation for offering high-quality products and services that reduce the burden for diabetes management. We set our high bar with our easy-to-use T-Slim X2 with control IQ technology. It continues to deliver outstanding clinical and quality of life improvements across a wide range of ages and demographics of people living with type 1 diabetes. This was recently highlighted in multiple publications, including the New England Journal of Medicine and Diabetes Technology and Therapeutics. The amount of positive data we are amassing for our market-leading AID capabilities is unrivaled. The New England Journal publication was the third time our T-SLIM was featured in the journal, this time focusing on the benefits of our control IQ technology for very young children. Diabetes Technology and Therapeutics recently published a meta-analysis of three randomized control IQ trials that demonstrated the immediate and sustained clinical benefit of our system. What this meta-analysis shows is that regardless of age, people with the highest baseline hemoglobin A1C and the lowest time and range experience the greatest benefit, which is important as we work to bring the benefits of our technology to more people living with diabetes. Our technology is not only making a positive clinical impact, but we are also making a positive impact on the environment. By choosing a T-Slim pump, our customers have kept more than 20 million batteries out of landfills since 2012. This is an important part of our longer-term product strategy, as we look forward to similar environmental benefits from our future product offerings. It's this kind of performance and impact, combined with the customer experience our teams provide, that sets Tandem apart and allows us to continue growing our installed base three years following the launch of ControlIQ. I'd now like to ask Brian and Lee to spend a few minutes talking about our performance in the first quarter, the broader commercial environment, and our expectations for the remainder of the year. Brian?